Trial Profile

A Phase 1, First-in-Human, Randomized, Observer-blind, Controlled, Dose-ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Seasonal Influenza Vaccine (ARCT-2138), When Administered to Healthy Adults

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARCT 2138 (Primary) ; Influenza vaccine (Optaflu); Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Arcturus Therapeutics

26 Jul 2024 Planned number of patients changed from 132 to 135.
26 Jul 2024 Planned End Date changed from 1 Oct 2024 to 1 Jan 2025.
26 Jul 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com